Chapter 6: Principles of Antimicrobial Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

We're aiming to give you that high yield shortcut today.

Right.

Not just listing drug names, but really getting into the core principles of antimicrobial pharmacotherapy.

Yeah, understanding the why.

Exactly.

It's essential stuff for anyone selecting or managing these pretty complex agents, especially in high stakes situations.

Absolutely.

So our mission today is really to build a systematic approach.

We want to talk about the how and the why mechanisms, pharmacokinetics, those critical safety bits.

The things that make a difference in practice.

Precisely.

We'll start with selection, cover the major drug classes, and definitely

Okay, let's dive in.

That systematic approach, where does it start?

Like patient comes in, you suspect infection, but no culture's back yet.

What's the thought process?

Well, it kicks off with understanding empiric versus definitive therapy.

Empiric is your first move.

Your educated guess.

Exactly.

It's time sensitive based on the likely infection site.

Say you suspect endocarditis, you're thinking staph aureus, maybe strep.

You cover the most probable bugs first.

Okay, so probability drives the initial choice.

But the goal is always to narrow it down, right?

How long until we get more specific?

Definitive therapy.

That's the goal.

And it hinges on getting the gram stain, the culture, the sensitivity tests back.

It usually takes about 48 to 72 hours.

So we start broad, then hopefully tailor it.

Yep.

Constantly aiming to narrow that spectrum once we know exactly what we're fighting.

Makes sense.

So beyond just guessing the bug for that empiric choice, what's the mental checklist?

What absolutely has to be considered?

Okay, four key things.

First,

source and site.

Can the drug actually get there?

Penetration's everything.

Right.

Second, acquisition site.

Is it community acquired or health care acquired?

Because health care acquired screams higher risk for MDR bugs needing broader coverage.

Okay, two more.

Third, efficacy versus toxicity.

Always a balance.

And fourth, the PK profile of pharmacokinetics and realistically cost.

You know, if the drug doesn't reach the site, it doesn't matter how good it looks on paper.

Failure is guaranteed if it can't get there.

Got it.

Okay, so therapy started.

We're monitoring.

What about de -escalation?

Moving from IV to oral seems like a huge goal.

Oh, it is.

Big win for the patient.

Big win for the hospital budget.

So what are the absolute must haves to make that switch?

You need three things happening at once.

One, clear clinical improvement.

Temperature coming down, white count normalizing, they're responding.

Okay.

Two, the patient has to be able to physically take oral meds and crucially absorb them properly.

And number three.

There needs to be a suitable oral equivalent.

It might be a different drug class sometimes, but it must cover the same bugs and have really good oral bioavailability.

But are there times when even if the patient looks better, we just switch to oral?

Absolutely.

There's a critical caveat.

Certain infections demand ongoing IV therapy.

Think osteomyelitis, bone infections,

or endocarditis.

These are deep -seated infections.

You need those high sustained drug levels you only really get with IV.

Okay, that framework is clear.

Now let's get into the drugs themselves.

Where's the best place to start?

The real cornerstones.

Got to start with the beta -lactams.

Penicillins, cephalosporins, carbapenems,

they're the workhorses.

And they all work the same basic way.

Fundamentally, yes.

They all mess with bacterial cell wall synthesis.

They bind to penicillin binding proteins.

PBPs stop the cell wall from building properly.

It's time -dependent killing.

Okay, penicillins first.

We group them by spectrum naturals, aminos, penicillinase resistant.

Now most are renal, right?

So dose adjustments are common.

Very common.

Adjusting for kidney function is standard procedure for most penicillins.

Are there exceptions we absolutely need to know?

Yes, a key pair.

Nafcillin and oxicillin.

These are the penicillinase -resistant ones.

They're cleared mainly by the liver, not the kidneys.

That's a huge distinction if your patient has renal impairment.

Good flag.

And side effects.

Mostly allergies.

Hypersensitivity.

Yeah, rashes.

High is most common.

But watch out for neurotoxicity, like seizures with really high doses, especially if kidney function is poor.

And that classic interaction, probenacid.

Right, probenacid blocks their secretion in the kidneys, makes them hang around longer, increases the half -life.

Okay, moving to cephalosporins.

Generations 1 through 5.

Generally, higher generation means better gram -negative coverage, maybe less gram -positive.

That's the general trend.

First gen, like cephasolin, great for skin stuff.

Surgical prophylaxis, mostly gram -positive focus.

Then you jump to, say, third gen cephalosporins.

Critical for meningitis.

Good CNS penetration.

Stronger gram -negative activity.

And the unique one, the MRSA killer.

That's fifth generation cephterylene.

It's the only cephalosporin that reliably covers MRSA.

You have to know that one.

NEPK pearls, like with the penicillins, an exception to renal excretion.

Yes, cephalosporin again.

Unlike most other cephalosporins, it's primarily eliminated by the liver.

Important for dosing.

Then we get to the big guns.

The carbapenems.

Imikenem, merapenem, dorbenem, urtapenem.

Broadest spectrum betel lactams we have.

Pretty much the broadest.

They cover gram -positives, gram -negatives, anaerobes.

Really wide coverage.

But there's always a catch, isn't there?

There is.

Urtapenem.

It's the odd one out.

Despite being a carbapenem, it has no useful activity against pseudomonas rudinosa or synatobacter.

Major gap.

If you suspect those, urtapenem is out.

Definitely out.

And the big safety concern with carbapenems.

Neurotoxicity.

Seizures are the main worry.

Is there difference between them?

Why might you pick merapenem over n -penem?

Imikenem seems to lower the seizure threshold more than the others.

So if a patient has a seizure history or other risks, merapenem or dorapenem are generally preferred.

They seem a bit safer from that perspective.

Okay.

And finally, how do we fight back when bacteria develop resistance within this class using those combo drugs?

Right.

The beta -lactam -beta -lactamase inhibitors or BLBLIs.

Think amoxicillin clavulinate or pipericillin tozobactam.

So an inhibitor just protects the main antibiotic.

Exactly.

The beta -lactamase inhibitor sacrifices itself, basically binding to the enzymes the bacteria produce to destroy the antibiotic.

Let's the beta -lactam do its job.

Crucial for mixed infections like intra -abdominal stuff, where those enzyme producers are common.

All right.

Let's shift gears.

Away from the cell wall,

what about drugs targeting the bacteria's internal machinery?

DNA protein synthesis.

Let's start with fluoroconolones.

FQs.

Okay.

FQs.

They hit DNA gyrase and topoisomerase OAV, right?

Stopping DNA replication.

Yep.

Very potent inhibitors.

And they work by concentration -dependent killing.

Plus, they generally have excellent bioavailability.

Which makes that IV to PO switch really attractive.

Very easy, usually.

Now, thinking about exceptions again, excretion.

Ah, right.

Most need renal dose adjustment, but moxaflaxacin is the exception.

Correct.

Moxaflaxacin is mostly non -renal elimination.

Spectrum -wise, they all hit gram negative aerobes well.

Cipro and Levo are notable for covering pseudomonas.

And they're oral options, which is handy.

The big but with FQs these days is the safety profile.

Those FDA warnings are pretty serious.

They are.

Disabling potentially permanent side effects.

Tendons, nerves, CNS effects.

It's a lot.

Does that mean we should really be holding them back, using them only when we have to?

It's generally the thinking.

Now, yes.

The risk -benefit calculation has definitely shifted.

We have to weigh those potential harms very carefully.

Plus, there's QTC prolongation to watch for.

And those interactions.

Oh, yeah.

Big ones.

Absorption gets tanked by things like antacids, iron, calcium.

Anything with divalent or trivalent intoracations.

You've got to separate the doses by hours.

And CIPR has that specific enzyme interaction.

Right.

Ciprofloxacin inhibits

CYP1A2.

That means it can boost levels of drugs like warfarin and theafiline.

You've got to watch that.

Okay.

Moving on.

Amulglycosides.

Gentamicin, tobromycin, amicacin.

Protein synthesis inhibitors.

Yes, they bind to the 30S ribosomal subunit.

Main use.

Serious gram -negative aerobic infections, including pseudomonas.

But what about gram -positives?

Can they work alone?

Not really effectively.

For gram -positives like staph or enterococcus, you need synergy.

You have to pair them with something that hits the cell wall.

A beta -lactam or vancomycin.

The cell wall agent helps the aminoglycoside get inside.

Makes sense.

But their use is always limited by?

Toxicity.

That's the major drawback.

Nephrotoxicity and ototoxicity.

Exactly.

Kidney damage, usually reversible if caught early.

And ear damage, hearing loss, balance problems, which can unfortunately be permanent.

What increases that risk?

High trough levels are a big factor.

That's why we monitor drug levels so closely.

Also using them with other toxic drugs like vancomycin itself or high dose loop diuretics like therosamides.

So monitoring levels is absolutely mandatory.

Non -negotiable, narrow therapeutic window.

Okay.

Last group in this section.

The macrolides.

Erythromycin, clarithromycin, azithromycin.

Also protein synthesis inhibitors, but they bind the 50S subunit.

Correct.

50S subunit.

Erythromycin is the older one.

Lots of GI upset.

Clarithromycin and azithromycin are generally better tolerated.

Azithromycin is the one with that super long half -life, right?

Yeah.

Incredibly long.

Like 50, 60 hours sometimes.

Allows for that Z -pack once daily dose inconvenience.

What about interactions?

Are they like Cipro?

Erythromycin and clarithromycin are potent inhibitors, but of a different enzyme,

CYP3A4.

This affects a lot of common drug statins, warfarin again, some calcium channel blockers.

But azithromycin is different.

Thankfully, yes.

Azithromycin has a much lower risk of those significant CYP3A4 interactions.

Makes it a bit easier to use in patients on multiple meds.

All right.

Let's focus on some specialists, particularly for tricky gram -positive bugs.

Vancomycin, the classic glycopeptide.

How does it work again?

Also cell wall.

Also cell wall active, yes, but a different mechanism than beta -lactams.

It targets the D -alanine part of the peptide chain used to build the cell wall, stops the cross -linking process further upstream.

Spectrum is pretty narrow, though.

Very narrow.

Primarily gram -positive aerobes and anaerobes, like MRSA, penicillin -resistant strep, and C.

difficile.

Okay.

Two absolute must -know pearls for Vanco.

One, oral vancomycin is only for C.

difficile colitis.

It stays in the gut, doesn't get absorbed systemically.

Zero use for infections outside the GI tract.

And two, IV vancomycin infusion rate.

Got to go slow.

At least over 60 minutes, sometimes longer for bigger doses, to avoid red man syndrome, that flushing, itching reaction.

Now, there's been a big shift in how we monitor Vanco lately, moving away from just checking troughs.

Yeah, the consensus guidelines have changed.

For serious infections like bacteremia or pneumonia, AUC -based monitoring is now recommended over trough only.

AUC area under the curve.

Why the change?

It's just a better marker, really.

It correlates better with both efficacy, killing the bug, and predicting the risk of nephrotoxicity.

It gives us a more precise way to dose.

More effective, potentially safer.

Okay.

Next up, daptomycin.

That's a lipopeptide, right?

Unique mechanism.

Very unique.

Daptomycin basically inserts itself into the bacterial cell membrane, causes rapid potassium afflux, depolarizes the membrane potential, and boom, cell death.

It's fast.

And it covers MRSA and VRE.

So, good for skin infections, bloodstream infections.

Exactly.

Complicated skin soft tissue infections, SREs, bacteremia, even right -sided endocarditis.

Great gram -positive coverage.

But here's the million dollar question.

If it's great against MRSA, why can't we use daptomycin for MRSA pneumonia?

The critical contraindication.

Daptomycin gets inactivated by pulmonary surfactant.

The substance lining the lungs renders it completely ineffective for pneumonia.

Cannot use it.

Wow.

Okay.

And another safety flag with daptomycin.

Muscle toxicity.

Yes.

Particularly when used with statins.

There's an increased risk of muscle pain, weakness, and elevated CPK levels.

Needs weekly CPK monitoring if given with a statin.

Good to know.

Quickly, the dedicated anti -anerobic agents, clindamycin and metronidazole.

Clinda's main issue.

High risk of C.

difficile colitis.

And frustratingly, that risk isn't related to the dose.

Any exposure can potentially trigger it.

And metronidazole.

Besides being great for anaerobes and BV.

Medallic taste is common.

Can cause some CNS effects.

But the crucial interaction is the disulfiram -like reaction with alcohol.

Nausea, vomiting, flushing, palpitations.

Patients must avoid all alcohol during therapy and for a few days after.

Cannot stress that enough.

Okay, we have to talk about antimicrobial resistance.

It's the elephant in the room for all these drugs.

What are the main ways bacteria fight back?

Our sources list about six common mechanisms.

We've touched on enzyme production, like beta -lactamers chewing up penicillins.

That's why we need those inhibitors.

Right.

What else?

How do they stop drugs getting in or kick them out?

Good question.

They can change their outer membrane.

Lose porins, the channels drugs use to enter.

Basically locking the door.

Or they can ramp up efflux pumps.

These are like pumps that actively push the antibiotic back out of the cell before it can work.

Very effective resistance strategy.

And sometimes they just change the target itself.

Exactly.

Like VRE, vancomycin -resistant enterococci.

They modify that D -alanine site.

So vancomycin literally can't bind anymore.

It forces us to develop completely new drug glasses.

Which leads us to antimicrobial stewardship.

What's the core idea there?

It's a coordinated effort, really.

Multidisciplinary.

The goal is simple, but vital.

Ensure the right drug at the right dose for the right duration for every patient.

Maximize cure.

Minimize resistance and toxicity.

How do we do that practically?

Strategies include using rapid diagnostic tests to identify the bug and its susceptibilities faster.

Optimizing dosing, using PKPD principles like that AUC monitoring for vanco we discussed.

And actively deescalating therapy whenever possible.

Don't use a broad spectrum when a targeted rifle will do.

So wrapping this up, understanding these details, the PK, the exceptions, the safety flags, it's what separates basic knowledge from advanced practice, isn't it?

Absolutely.

Knowing vancomycin treats MRSA is one thing.

Knowing how to dose it with AUC monitoring when not to use oral vanco, how to manage red man syndrome, that's clinical mastery.

It really makes you think,

are you just treating the bug listed on the culture report?

Or are you

seizure risk with carbapenems that statin they're taking with Daptomycin?

That's the core question, isn't it?

That holistic view, integrating pharmacology with the patient's specific situation.

That's what truly defines advanced pharmacotherapy and leads to better, safer outcomes.

Well said.

This has been incredibly insightful.

Thank you for taking us on this deep dive into antimicrobial principles.

My pleasure.

Always important to revisit these foundations.

And thank you all for listening.

We hope this helps you navigate these critical medications with more confidence.

Until next time.